Panomics has announced the joint publication of the 'Evaluation of DNA Microarray results with quantitative gene expression platforms' in the 8 September 2006 issue of Nature Biotechnology
This study was a part of the two year initiative led by the FDA.
The studies published in the 8 September 2006 issue of Nature Biotechnology, discuss various elements of the program, including the evaluation of a number of non-microarray based quantitative gene expression platforms.
The aim of this supporting study (Nature Biotechnology, volume 24, pp 1115-1122) was to compare the performance characteristics of three quantitative gene expression technologies.
"We are very pleased that in a number of key areas, including accuracy and precision, QuantiGene outperformed established PCR based methods such as TaqMan" said Yuling Luo, vice president, functional genomics at Panomics.
"We encourage the research community to critically evaluate the manuscript and to review the data.
"We feel the results overwhelmingly demonstrate our position that QuantiGene not only offers obvious workflow advantages over PCR based methods but also offers superior results.
"Central to bDNA-based gene expression analysis is the direct measurement of mRNA transcripts at its source.
"We strongly believe that the avoidance of RNA purification, reverse transcription, and target amplification contribute to the high level of accuracy and precision offered by QuantiGene assay."
